Compare Charles River Laboratories Intl. Inc (CRL) vs Freeport-McMoRan Inc (FCX) Price & Performance

Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.

CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.

FCX trades at $71.13, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.68 exceeding the $0.60 estimate. Revenue for 2025 was $25.92B, with net income of $2.20B and an 11.38% net margin. Analyst consensus is a Buy with a $73.27 price target, and recent news highlights copper demand growth driven by AI and data centers.

FCX presents a positive outlook supported by robust copper demand trends and expansion projects, though rising production costs and a bearish technical picture pose near-term risks. The stock offers potential upside to the consensus target, but investors should monitor cost pressures and quarterly execution against expectations.